Paul E. Sax
Contributing Editor at NEJM Journal Watch
Editor-in-Chief/Clinical Director at Clinical Infection in Practice
Harvard/Brigham Infectious Diseases doctor, writer, @CIDJournal editor, educator. Prefer baseball to football, pizza to sushi, dogs to cats, Beatles to Stones.
Articles
-
1 week ago |
blogs.jwatch.org | Paul E. Sax
Back in prehistoric times, many ID doctors and microbiologists would gather each fall at a meeting to review the latest antimicrobial clinical trials and promising "bug-drug" studies of novel compounds in development. The meeting was called the Interscience Conference on Antimicrobial Agents and Chemotherapy, abbreviated ICAAC. There were a bunch of problems with ICAAC. First, everyone associates "chemotherapy" with cancer treatment, which of course this wasn't.
-
3 weeks ago |
blogs.jwatch.org | Paul E. Sax
Imagine you're birdwatching in the Costa Rican rainforest, Merlin app in hand. A flash of iridescent blue catches your eye. You scan the canopy and whisper excitedly:Look, it's the elusive Blujepa! A rare sighting!No, not a real bird, but Blujepa is the brand name of gepotidacin, something rarer - and arguably more exciting - than a tropical bird, at least to us ID geeks: a brand new antibiotic class for treatment of uncomplicated urinary tract infections.
-
1 month ago |
blogs.jwatch.org | Paul E. Sax
Wow, that was an interesting conference - in ways both good and bad. The good part was the content, as the Conference on Retroviruses and Opportunistic Infections (CROI) is our leading HIV research conference. There was plenty of interesting stuff. The not-so-good part was the stunned state of many HIV clinicians and researchers.
-
1 month ago |
blogs.jwatch.org | Paul E. Sax
In this raging flu season, where people with influenza-related illness outnumber those with COVID-19 for the first time since the pandemic hit in 2020, we might be fooled into thinking that we no longer need better treatments for COVID-19. This would be a mistake - this virus still causes much misery, peaking each winter but circulating year-round, destabilizing lives everywhere. But how will we get these better treatments?
-
1 month ago |
blogs.jwatch.org | Paul E. Sax
My ID colleague Dr. Adam Ratner, Chief of Pediatric ID at NYU Medical Center, just published an insightful and remarkably timely book called Booster Shots: The Urgent Lessons of Measles and the Uncertain Future of Children's Health. Chapter Six is entitled "Making Nothing Happen," and it starts off with this especially profound paragraph:Prevention can be a tough business.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 57K
- Tweets
- 5K
- DMs Open
- No
The SNAP trial may finally resolve some of the longest-running debates in SAB management (cefazolin vs semi-synthetic PCN? Is PCN really active vs PSSA?). Congrats to @syctong @Josh_S_Davis, and the global team who made this ambitious trial happen. https://t.co/n8ZXrqrRM6
Remember ICAAC? Bad name, weirder pronunciation ("ick-kack"), and a classic case study in conference identity crisis. A look back—and where the big ID trials land now, which is @ESCMID Global. Following closely! #IDSky https://t.co/jAeZmRO3m4
Latest post on a new antibiotic, gepotidacin, which has a novel mechanism of action, is the first new drug for uncomplicated UTIs in decades, and has a brand name that sounds a lot like a tropical bird. Plus some digressions on prog rock, for no reason. https://t.co/CLkO65yo3O
